Printer Friendly

MAGAININ PHARMACEUTICALS INC. ANNOUNCES MANUFACTURING PROCESS BREAKTHROUGH FOR ITS LEAD DRUG, MSI-78

 MAGAININ PHARMACEUTICALS INC. ANNOUNCES MANUFACTURING PROCESS
 BREAKTHROUGH FOR ITS LEAD DRUG, MSI-78
 PLYMOUTH MEETING, Pa., Nov. 9 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced that its scientists have developed a recombinant process for synthesizing MSI-78, the company's broad-spectrum, topical, antibacterial and antifungal drug currently in Phase I Human Clinical Trials. MSI-78 is being targeted for use in serious infections, including impetigo, infected surgical wounds, diabetic ulcers, decubitus ulcers and burns.
 "We believe that Magainin scientists have crossed a major hurdle in the cost-effective production of MSI-78. The production of peptides, such as MSI-78, through solid and solution phase chemistry has traditionally been expensive. If the clinical trials are successful and MSI-78 is approved by the FDA, the ability to synthesize MSI-78 through recombinant technology should allow us to provide MSI-78 at a cost competitive with other antibiotics," said Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals Inc. In addition, a patent is pending on a novel purification technology for recombinant antimicrobial peptides that could further reduce production costs for the magainin peptides. These scientific achievements may have application for a number of the drugs Magainin is developing."
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of therapeutic products derived from various host defense systems for the treatment of infections and certain cancers and the promotion of wound healing.
 -0- 11/9/92
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals Inc., 215-941-4020, or Fern Lazar of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals Inc./
 (MAGN) CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU:


CK-OS -- NY033 -- 8594 11/09/92 10:18 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1992
Words:269
Previous Article:FIRSTAT OF AMERICA ANNOUNCES CLEVELAND OPENING
Next Article:MAXXAM INC. CHAIRMAN HURWITZ ISSUES STATEMENT CONCERNING CONTINENTAL AIRLINES
Topics:


Related Articles
MAGAININ PHARMACEUTICALS ANNOUNCES FORMATION OF NEW INSTITUTE TO BE DIRECTED BY DR. MICHAEL ZASLOFF
MAGAININ'S LEAD DRUG CANDIDATE TO ENTER PIVOTAL PHASE IIB/III CLINICAL TRIALS
MAGAININ PHARMACEUTICALS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
MAGAININ PHARMACEUTICALS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
Magainin Pharmaceuticals Raises $12 Million in Private Placement
Magainin Announces Successful MSI-78 Phase III Trial Results
Houghten Pharmaceuticals Receives Stock in Exchange for Royalty Interest in Magainin's Lead Compound
Magainin Pharmaceuticals Buys Out MSI-78 Royalty Stream
Magainin Announces Cytolex Collaboration with SmithKline Beecham in North America
Magainin Announces Successful Results of Second Pivotal Trial For Cytolex (MSI-78)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters